base metals investing Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease Conference
base metals investing Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease Conference
THE Mining Investment Event 2026 Announces Keynote Speakers and Panels, Additional Sponsors and Participating Companies
Kobo Resources Announces Closing of Non-Brokered Private Placement for Gross Proceeds of $5.5 Million and Engagement of Atrium Research
